Charles River Laboratories International, Inc. (CRL) Stock

Understand Charles River Laboratories International, Inc.: how it makes money

Charles River Labs runs preclinical drug-discovery and safety-testing services for pharma and biotech clients worldwide, earning fees for lab hours, rodent models, and small-batch manufacturing. About three-fifths of revenue comes from DSA (toxicology and efficacy studies), with the rest split between purpose-bred animal sales and the emerging cell-therapy manufacturing line.

Revenue is a pass-through on pharma R&D budgets: CRL is paid for months of lab hours and animal models per compound, so the topline tracks how many drugs enter non-clinical safety testing rather than a repeatable product sale.

Business quality (Weak): Revenue is contractively flat, ROE sits at negative 8 percent, and the upgrade-grade label reads Weak, but the $295 million savings program and a $1 billion buyback signal management is actively re-engineering the cost base to defend the 12 percent operating margin.

Bull case

• Aggressive cost restructuring underway: Management targets $295 million of annualized savings in FY26 through restructuring and efficiency actions, which at roughly 30 percent of quarterly revenue would meaningfully lift the 12 percent operating margin once fully phased in.
• Biotech pipeline reaccelerating: New biotech proposals grew at a high-single-digit rate both year over year and sequentially in Q3 FY25, suggesting the demand trough is passing and future DSA bookings should firm.
• Cash-rich and returning capital: Free cash flow now supports a new $1 billion share repurchase authorization alongside a $0.30 annualized EPS accretion from divestitures, giving the stock a floor from balance-sheet strength.

Bear case

• DSA backlog still shrinking: The DSA backlog fell from $1.93 billion to $1.80 billion, a 7 percent drawdown that signals committed work is contracting even as new proposals improve, meaning revenue inflection may take two or more quarters.
• Client concentration bites in CDMO: The loss of a single cell-therapy client creates a $20 million second-half revenue headwind in Manufacturing, a segment that is only $190 million a quarter, underscoring how a few large relationships can move the line.
• Tax drag compresses net income: The effective tax rate rose 700 basis points year over year, directly reducing EPS and partially offsetting the earnings benefit from the $295 million savings program.

Related Companies (Business Services; 8 comparable business services companies)

• Medpace Holdings, Inc. (MEDP)
• Incyte Corporation (INCY)
• IQVIA Holdings Inc. (IQV)
• UL Solutions Inc. (ULS)
• The Western Union Company (WU)
• Shift4 Payments, Inc. (FOUR)
• NIQ Global Intelligence Plc (NIQ)
• Akamai Technologies, Inc. (AKAM)